Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus

Atara Biotherapeutics jumped roughly 18% late Monday morning, rallying alongside other rare-disease biotech stocks after word got out that the FDA’s head of biologics is set to depart next month. uniQure picked up about 15%, while Regenxbio climbed close to 20%.

Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials

Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials

• Denali Therapeutics shares climbed in afternoon trading, gaining ground while the broader biotech sector remained flat.• Attention intensified following the FDA’s decision to halt Regenxbio’s rare-disease gene therapy trials.• Investors are now zeroed in on Denali’s FDA timeline for its Hunter syndrome treatment and the data update expected in early February.
Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

The first half of 2025 has seen biotechnology and health technology sectors accelerate on multiple fronts, from groundbreaking scientific advances to robust deal-making. Industry optimism is high – a Deloitte survey of 150 life science executives found 75% believe 2025 will be a strong year, citing anticipated revenue growth and rapid innovation genengnews.com. This optimism is translating into action, with emerging technologies like gene editing, precision medicine, digital health, and AI reaching new milestones. Meanwhile, global market projections remain bullish: for example, the AI in healthcare market is projected to grow about 10-fold from ~$15 billion in 2024 to over $164 billion by 2030 globenewswire.com, and the digital health market is expected to soar past $1 trillion by the early 2030s precedenceresearch.com.

US Stock Market Today Updates

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 Strong Buy

NVIDIA

94/100
#2 Strong Buy

Meta Platforms

89/100
#3 Buy

Alphabet

87/100
#4 Buy

Amazon

84/100
#5 Selective Buy

Microsoft

82/100
View full portfolio
Editorial model selection. Not personalised advice.